<DOC>
	<DOCNO>NCT00852371</DOCNO>
	<brief_summary>This randomize , single-blinded , placebo-controlled trial evaluate efficacy , safety tolerability antimalarial regimens healthy schoolchildren . The primary objective study compare efficacy different combination antimalarial regimen , include amodiaquine + sulfadoxine-pyrimethamine ( AQ+SP ) , dihydroartemisinin-piperaquine ( DP ) , placebo , SP intermittent preventive treatment ( IPT ) schoolchildren , measure risk parasitaemia ( unadjusted genotyping ) 42 day follow-up . This assess efficacy treatment asymptomatic infection efficacy prevention new infection .</brief_summary>
	<brief_title>Intermittent Preventive Treatment Malaria Schoolchildren</brief_title>
	<detailed_description>The study carry among child age ≥ 8 &lt; 14 year ( boy ) ≥ 8 &lt; 12 year ( girl ) attend primary school Tororo district . Schools select use convenience sample assistance district education sector . The target population include child attend primary school Uganda . The accessible population include child attend participate primary school class 3-7 Tororo district . Children meet selection criterion participation study randomize treatment one four study regimen follow 42 day . Repeat evaluation perform day 1 , 2 , 3 , 7 , 14 , 28 , 42 ( unscheduled day student ill ) include assessment occurrence adverse event . Treatment efficacy outcome assess use revise WHO outcome classification criterion . Acceptability treatment regimen assess use questionnaire administer participating student day 7 . The primary outcome measure risk parasitaemia ( unadjusted genotyping ) 42 day follow-up .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Fanasil , pyrimethamine drug combination</mesh_term>
	<mesh_term>Sulfadoxine</mesh_term>
	<mesh_term>Amodiaquine</mesh_term>
	<mesh_term>Dihydroartemisinin</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<mesh_term>Pyrimethamine</mesh_term>
	<mesh_term>Piperaquine</mesh_term>
	<criteria>Age ≥ 8 &lt; 14 year ( boy ) , ≥ 8 &lt; 12 year ( girl ) Student enrol participate school class 37 Provision inform consent parent guardian Provision assent student Known allergy history adverse reaction study medication Onset menstruation ( girl ) Fever ( ≥ 37.5°C axillary ) history fever previous 24 hour Evidence severe malaria danger sign Haemoglobin &lt; 7.0 gm/dL Parasite density &gt; 10,000/ul</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>13 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Malaria</keyword>
	<keyword>Intermittent preventive treatment</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Safety</keyword>
	<keyword>Tolerability</keyword>
	<keyword>Schoolchildren</keyword>
	<keyword>Uganda</keyword>
</DOC>